Intracerebral hemorrhage in COVID-19 patients with pulmonary failure – a propensity score matched registry study
Abstract Background: Hypercoagulopathy in coronavirus disease 2019 (COVID-19) causing deep vein thrombosis and pulmonary artery embolism necessitate systemic anticoagulation. Case reports of intracerebral hemorrhages in ventilated COVID-19 patients warrant precaution. It is unclear however, if COVID-19 patients with acute respiratory distress syndrome (ARDS) with and without extracorporeal membrane oxygenation therapy (ECMO) have more intracerebral hemorrhages (ICH) compared to other ARDS patients.Methods: We conducted a retrospective observational single center study enrolling all patients with ARDS from 01/2018-05/2020. Patients with ARDS positive for SARS-CoV2 PCR were allocated to the COVID-19 group. Propensity score matching was performed for age, ECMO and risk of bleeding according to HAS-BLED score.Results: A total of 163, mostly severe ARDS patients were identified, 116 (71.2%) without COVID-19 and 47 (28.8%) positive for SARS-CoV-2. The two groups were comparable concerning the main confounders of ICH including age, HAS-BLED score, need for ECMO-therapy as well as anticoagulation levels reported. In 63/163 cases (38.7%), veno-venous ECMO therapy was required and ICU survival was 52.8%. Although HAS-BLED-score on admission was generally low (1.6±1.3), intracerebral hemorrhage was detected in 22 patients (13.5%) with no statistical difference between the groups (11.2 vs. 19.1% with and without SARS-CoV-2, respectively, p=0.21). Propensity score matching confirmed similar intracerebral bleeding rates in both groups (12.8 vs. 19.1% with and without SARS-CoV-2, respectively, p=0.57). Conclusions: Intracerebral hemorrhage was detectable in every tenth patient with ARDS. We found no statistically significant increased bleeding rate in patients with ARDS due to COVID-19 compared to other causes of ARDS..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
ResearchSquare.com - (2022) vom: 28. Juli Zur Gesamtaufnahme - year:2022 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lang, Corinna N. [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
doi: |
10.21203/rs.3.rs-56258/v1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XRA03343350X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XRA03343350X | ||
003 | DE-627 | ||
005 | 20230429191207.0 | ||
007 | cr uuu---uuuuu | ||
008 | 220113s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.21203/rs.3.rs-56258/v1 |2 doi | |
035 | |a (DE-627)XRA03343350X | ||
035 | |a (ResearchSquare)10.21203/rs.3.rs-56258/v1 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lang, Corinna N. |e verfasserin |4 aut | |
245 | 1 | 0 | |a Intracerebral hemorrhage in COVID-19 patients with pulmonary failure – a propensity score matched registry study |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Background: Hypercoagulopathy in coronavirus disease 2019 (COVID-19) causing deep vein thrombosis and pulmonary artery embolism necessitate systemic anticoagulation. Case reports of intracerebral hemorrhages in ventilated COVID-19 patients warrant precaution. It is unclear however, if COVID-19 patients with acute respiratory distress syndrome (ARDS) with and without extracorporeal membrane oxygenation therapy (ECMO) have more intracerebral hemorrhages (ICH) compared to other ARDS patients.Methods: We conducted a retrospective observational single center study enrolling all patients with ARDS from 01/2018-05/2020. Patients with ARDS positive for SARS-CoV2 PCR were allocated to the COVID-19 group. Propensity score matching was performed for age, ECMO and risk of bleeding according to HAS-BLED score.Results: A total of 163, mostly severe ARDS patients were identified, 116 (71.2%) without COVID-19 and 47 (28.8%) positive for SARS-CoV-2. The two groups were comparable concerning the main confounders of ICH including age, HAS-BLED score, need for ECMO-therapy as well as anticoagulation levels reported. In 63/163 cases (38.7%), veno-venous ECMO therapy was required and ICU survival was 52.8%. Although HAS-BLED-score on admission was generally low (1.6±1.3), intracerebral hemorrhage was detected in 22 patients (13.5%) with no statistical difference between the groups (11.2 vs. 19.1% with and without SARS-CoV-2, respectively, p=0.21). Propensity score matching confirmed similar intracerebral bleeding rates in both groups (12.8 vs. 19.1% with and without SARS-CoV-2, respectively, p=0.57). Conclusions: Intracerebral hemorrhage was detectable in every tenth patient with ARDS. We found no statistically significant increased bleeding rate in patients with ARDS due to COVID-19 compared to other causes of ARDS. | ||
650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
700 | 1 | |a Dettinger, Johanna S. |e verfasserin |4 aut | |
700 | 1 | |a Berchtold-Herz, Michael |e verfasserin |4 aut | |
700 | 1 | |a Utzolino, Stefan |e verfasserin |4 aut | |
700 | 1 | |a Bemtgen, Xavier |e verfasserin |4 aut | |
700 | 1 | |a Zotzmann, Viviane |e verfasserin |4 aut | |
700 | 1 | |a Schmid, Bonaventura |e verfasserin |4 aut | |
700 | 1 | |a Biever, Paul M. |e verfasserin |4 aut | |
700 | 1 | |a Bode, Christoph |e verfasserin |4 aut | |
700 | 1 | |a Müller-Peltzer, Katharina |e verfasserin |4 aut | |
700 | 1 | |a Duerschmied, Daniel |e verfasserin |4 aut | |
700 | 1 | |a Wengenmayer, Tobias |e verfasserin |4 aut | |
700 | 1 | |a Niesen, Wolf-Dirk |e verfasserin |4 aut | |
700 | 1 | |a Staudacher, Dawid L. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2022) vom: 28. Juli |
773 | 1 | 8 | |g year:2022 |g day:28 |g month:07 |
856 | 4 | 0 | |u https://doi.org/10.1007/s12028-021-01202-7 |z lizenzpflichtig |3 Volltext |
856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-56258/v1 |z kostenfrei |3 Volltext |
912 | |a GBV_XRA | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2022 |b 28 |c 07 |